ODE (office of device evaluation) deputy steps up to top role
This article was originally published in Clinica
Executive Summary
Daniel Schultz, deputy director for clinical and review policy at the US FDA's office of device evaluation (ODE), has moved up to become office director. He replaces Bernard Statland, who left this week to return to law school. "Dan brings to the job a wealth of clinical and administrative experience that should prove invaluable in overseeing the evaluation of new medical devices," David Feigal, director of the Center for Devices and Radiological Health said in announcing the appointment.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.